November 24, 2016 - By Linda Rogers · 0 Comments
The stock of Apricus Biosciences Incorporated (NASDAQ:APRI) registered an increase of 18.32% in short interest. APRI’s total short interest was 279,000 shares in November as published by FINRA. Its up 18.32% from 235,800 shares, reported previously. With 81,900 shares average volume, it will take short sellers 3 days to cover their APRI’s short positions. The stock increased 2.56% or $0.04 on November 23, hitting $1.6. About 51,135 shares traded hands. Apricus Biosciences Inc (NASDAQ:APRI) has declined 69.81% since April 22, 2016 and is downtrending. It has underperformed by 75.22% the S&P500.
Apricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The company has a market cap of $11.84 million. The Firm primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. It currently has negative earnings. The Company’s drug delivery technology is a permeation enhancer called NexACT.
Out of 5 analysts covering Apricus Bioscience Inc (NASDAQ:APRI), 2 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 40% are positive. Apricus Bioscience Inc has been the topic of 6 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The rating was maintained by FBR Capital on Friday, November 6 with “Outperform”. On Thursday, August 13 the stock rating was initiated by Ascendiant Capital Markets with “Buy”. The firm has “Neutral” rating by TH Capital given on Friday, November 6. On Friday, November 6 the stock rating was downgraded by Roth Capital to “Neutral”. Sterne Agee CRT downgraded the stock to “Neutral” rating in Wednesday, December 9 report.
Apricus Biosciences, Inc., incorporated on October 20, 1987, is a pharmaceutical company, which develops pharmaceutical products. The Firm primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT. It has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud’s phenomenon, secondary to scleroderma. The Firm has a commercial product, Vitaros for the treatment of erectile dysfunction (ED), which is in development in the United States, approved in Canada and marketed throughout Europe.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Linda Rogers